Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

泰瑞沙 - NMPA Drug Approval Details

Approvals/NMPA/Osimertinib Mesylate Tablets

Approved

化学药品

Osimertinib Mesylate Tablets

ASTRAZENECA AB🇨🇳 National Medical Products Administration

Approval Date: Feb 11, 2026
Approval ID: 8CYngvL4Dcc
Company: ASTRAZENECA AB
Type: 化学药品

Approval Details

Approval Id: 8CYngvL4Dcc
Approval Number: 国药准字HJ20181062
Generic Name: 甲磺酸奥希替尼片
Generic Name En: Osimertinib Mesylate Tablets
Trade Name: 泰瑞沙
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 40mg(按C₂₈H₃₃N₇O₂计)
Reg Date: 2026-02-11
Expired Date: 2031-02-10
Company Name: ASTRAZENECA AB
Production Company Name: ASTRAZENECA AB
Company Detail Path: /organization/ebf50ffbadeec5e9/astrazeneca-ab
Production Company Detail Path: /organization/ebf50ffbadeec5e9/astrazeneca-ab

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Feb 11, 2026

Approval ID

8CYngvL4Dcc

Type

化学药品

Back to NMPA Approvals